Explore the words cloud of the Trep-AB project. It provides you a very rough idea of what is the project "Trep-AB" about.
The following table provides information about the project.
Coordinator |
FUNDACION PRIVADA DE LUCHA CONTRA EL SIDA
Organization address contact info |
Coordinator Country | Spain [ES] |
Total cost | 1˙498˙790 € |
EC max contribution | 1˙498˙790 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2019-STG |
Funding Scheme | ERC-STG |
Starting year | 2020 |
Duration (year-month-day) | from 2020-02-01 to 2025-01-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | FUNDACION PRIVADA DE LUCHA CONTRA EL SIDA | ES (BADALONA) | coordinator | 1˙150˙678.00 |
2 | UNIVERSITY OF WASHINGTON | US (SEATTLE WA) | participant | 348˙111.00 |
Current therapeutic options for human treponematoses, syphilis and yaws, are, broadly speaking, restricted to one antibiotic: injectable penicillin. The drug susceptibility profile of Treponema pallidum (T.p) is unknown because the microorganism could not be grown in culture. Treatment failure after penicillin has been related to syphilis bacteria that survive in the central nervous system (CNS) and the potential of strains to acquire resistance to penicillin has recently been recognized. Yaws can be treated with azithromycin but there is a real risk that macrolide-resistant strains disseminate widely and jeopardize the global eradication campaign. I propose a research program to have other validated treatment options with good CNS penetration that are efficacious for all the stages of treponemal infection. Our preliminary results using computational prediction of drug activity based on similarity to drugs with known activity against T.p. and other spirochetes shows several candidate antibiotics. I will take advantage of recent developments in culture methods for determination of drug susceptibility to test 20 prioritized drugs. These results will be confirmed in experimentally infected rabbits treated with the investigational drugs and assessed for lesion development and T.p. burden. My second approach will exploit the established expertise of my team conducting randomized clinical trials to evaluate the efficacy of the 2 most promising candidates compared to standard treatment to cure patients with syphilis/yaws. Such studies will incorporate in-depth studies of recurrent events among study participants, to further clarify the biological basis and identify mutations that confer resistance to B-lactams. New antibacterial oral drugs for the treatment of treponematoses will be a tremendous resource in case of penicillin treatment-failure, resistance, shortage, allergy, or for use in yaws combination regimens to reduce the likelihood of resistance selection.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TREP-AB" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TREP-AB" are provided by the European Opendata Portal: CORDIS opendata.